These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3144221)

  • 1. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco.
    Slutkin G; Schecter GF; Hopewell PC
    Am Rev Respir Dis; 1988 Dec; 138(6):1622-4. PubMed ID: 3144221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1975 Jan; 1(7899):119-24. PubMed ID: 46047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
    Small PM; Schecter GF; Goodman PC; Sande MA; Chaisson RE; Hopewell PC
    N Engl J Med; 1991 Jan; 324(5):289-94. PubMed ID: 1898769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW; Snider DE; Farer LS
    Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
    Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
    Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
    Jones BE; Otaya M; Antoniskis D; Sian S; Wang F; Mercado A; Davidson PT; Barnes PF
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1499-502. PubMed ID: 7952606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smear-negative, culture-positive pulmonary tuberculosis. Six-month chemotherapy with isoniazid and rifampin.
    Dutt AK; Moers D; Stead WW
    Am Rev Respir Dis; 1990 May; 141(5 Pt 1):1232-5. PubMed ID: 2111106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
    Snider DE; Graczyk J; Bek E; Rogowski J
    Am Rev Respir Dis; 1984 Dec; 130(6):1091-4. PubMed ID: 6508006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of treatment with rifampicin and isoniazid in association with ethambutol or prothionamide in patients with recently detected pulmonary tuberculosis].
    Homenko AG; Ciukanov VL
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1979; 28(4):211-8. PubMed ID: 232302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1976 Nov; 2(7995):1102-4. PubMed ID: 62946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
    Br J Dis Chest; 1984 Oct; 78(4):330-6. PubMed ID: 6386028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.